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Abstract  
BACKGROUND: Colorectal cancer (CRC) is the second commonest cancer in women, the third in men, being the 
fourth commonest cause of cancer death. The most important factor for prognosis and staging in CRC patients is 
the status of the regional lymph nodes (LN). 
AIM: To implement the method for sentinel lymph node (SLN) detection in CRC patients using radiocolloid, and 
test its detection rate, sensitivity, accuracy, negative predictive value and the possibility for upstaging. 
MATERIAL AND METHODS: The study included 40 CRC patients, age 63 ± 14 years, without LNs detected on 
CT or MRI. SLN detection was performed after endoscopically peri- and intratumoral injection of 99mTc-
SENTISCINT. All patients underwent resection with systemic lymphadenectomy, and the SLNs were detected ex 
vivo. Pathohistology was performed to all resected LNs. 
RESULTS: The identification rate was 95%, the accuracy of the procedure was 92.1%, the negative predictive 
value was 86.95%, the sensitivity was 83.3%, and the upstage was 22.5%. 
CONCLUSION: Identification of SLNs in CRC patients with this method is possible and the detection rate, 
negative predictive value, accuracy and sensitivity are reliable. We expect to contribute in the upstaging of stage II 
CRC patients and the selection of appropriate oncology treatment protocols. 
 
 
 
 
Introduction 
 
Colorectal cancer (CRC), as of 2012, is 
classified as the second most common cause of 
cancer among women (9.2% of diagnoses) and the 
third most common among men (10.0% of diagnoses). 
Also, according to the WHO reports, it is the fourth 
most common cause of cancer death after lung, 
stomach and liver cancer. Globally more than 1 million 
people are diagnosed with CRC each year [1]. The 
incidence in our country, -according to the data 
published by the ministry of health, is 25.7/100.000 
population, which results in 500-600 newly diagnosed 
cases per year. Unfortunately, 65-70% of them are in 
the high stage III with locoregional disease spread 
and lymph node metastases. The most important 
factor for prognosis and staging in CRC patients is the 
status of the regional lymph nodes (LN) [2]. The 5-
year survival rate in patients with loco regional LNs 
positive for metastases is 25-30% lower compared to 
patients with disease free LNs [3]. The presence of 
affected LNs determinates the disease stage and the 
possible adjuvant chemotherapy inclusion which, on 
the other hand, influences the rate of disease 
recurrence, 5-year disease free period and the overall 
survival rate. Thus, the appropriate staging and 
treatment of CRC patients decrease the recurrence 
rate by 40% and the mortality rate by 33% [4]. The 
staging of CRC patients is performed according to the 
TNM classification. 
Stage I and II patients (No; Mo), according to 
the recommendations of the American Joint 
Committee on Cancer (AJCC), undergo only surgical 
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resection and lymphadenectomy and no adjuvant 
therapy is included [5, 6]. Stage III patients (N+), 
according to the recommendations of the AJCC, 
undergo surgical treatment and standard adjuvant 
chemo therapy, usually with 5-Fluorouracil [6].  
Table 1: TNM classification of CRC 
 
 
The most significant criteria according to 
which patients are classified into stage II or stage III is 
the affection of the LNs with metastatic deposits. 
Table 2 – Stage II and Stage III characteristics for CRC patients 
 
Chemotherapy is not considered to be 
standard of care in stage II patients since it proves no 
benefits for LN negative disease and also inflicts 
multiple adverse effects. It has to be taken into 
consideration, however, that this recommendation is 
only valid when the CRC staging is precise and 
accurate. Unfortunately, 25-30% of the stage II 
patients experience loco-regional disease recurrence 
or metastatic disease [3]. The SEER study 
(Surveillance, Epidemiology and End Results) 
presents a dilemma about the survival rate between 
stage IIB/C and stage IIIA patients. The 5-year 
survival rate in patient’s stage IIB/C is 72.2%, and in 
the stage, IIIA is 83.4% due to the adjuvant therapy 
included in stage III [7]. 
This could be either due to inappropriate or 
inaccurate staging procedures, a low number of 
harvested LNs or aberrant lymphatic drainage which 
leads to final downstaging of this subgroup of patients. 
The result is the exclusion of adjuvant chemotherapy 
in otherwise LN positive patients and thus worse 
overall survival rate and 5-year disease free period. 
The standard nodal staging technique is based on the 
histopathological evaluation on one or two LN 
sections with hematoxylin and eosin (H&E) staining, 
and the risk probability of missing metastases with this 
procedure is relatively high [8]. Introduction of 
multisection LN analysis, immunohistochemistry (ICH) 
and molecular reverse transcription polymerase chain 
reaction (RT-PCR) increases the accuracy of staging, 
but at the same time is expensive, time-consuming 
and impractical to be performed on all LNs.  
The sentinel lymph node (SLN) is considered 
to be the first barrier of metastatic disease. SLN 
biopsy has proven to be reliable in predicting the 
nodal status for specific subsets of melanoma and 
breast cancer patients [9-11]. The concept of SLN 
mapping in CRC is a prediction of the nodal status 
and increase the accuracy of nodal staging by 
selecting one or several LNs for detailed 
histopathological analysis, especially in the high-risk 
stage II patients, and at the same time, no reduction 
or alteration in the surgical procedure [12]. 
This study aimed to implement the method for 
SLN detection in CRC patients using radiocolloid and 
test its detection rate, sensitivity, accuracy, negative 
predictive value and the possibility for upstaging. 
 
 
Material and Methods 
 
The study was performed as a controlled 
prospective trial at the University Clinic for Digestive 
surgery-Skopje, the Institute for Nuclear Medicine-
Skopje, the University Clinic for 
Gastroenterohepatology-Skopje and the Institute for 
Pathology-Skopje, in the period January 2013 - 
January 2015. Eighty CRC patients (40 + 40) 
confirmed on endoscopy (colonoscopy) and biopsy, 
age 63 ± 14 years, preoperatively classified as stage I 
or II, without LNs detected on CT or MRI were 
included. All patients (pts) were familiarized with the 
procedure and written informed consent was obtained. 
Exclusion criteria were: stage III or IV pts with LN 
metastases (N+) or distant metastases (M+), 
preoperative adjuvant chemotherapy and previous 
surgical resection. All surgical interventions were 
performed by one surgeon, all endoscopies by one 
endoscopist, all scintigraphy findings interpreted by 
one nuclear medicine specialist and all 
pathophysiology analysis conducted by one 
pathologist, all of the above mentioned with at least 
ten years experience in the appropriate field of 
expertise. 
SLN detection was performed in 40 CRC 
patients, and it included peri endoscopically- and 
intratumoral injection (24 h prior to the surgical 
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procedure) of 4 mCi/4 ml (150 MBq) 99m-Technetium-
SENTISCINT, subdivided into 4 separate doses (each 
dose of 1 mCi/1 ml (37 MBq) respectively per injection 
site) and injected into 4 separate locations through an 
endoscopic needle. Three of the injections were 
peritumoral, submucosa, and were injected clockwise 
at 120 circle degrees around a tumour, and one 
injection was intratumoral. All endoscopic procedures 
were video monitored and filmed. In case of 
intravascular application, the SLN detection procedure 
was considered unsuccessful. Because radiotracers 
were used, all endoscopic applications were 
performed according to the ALARA principles (best 
diagnostic presentation with the minimum radiation 
burden to the patient). 
SENTISCINT is a MEDI-RADIOPHARMA 
LTD Hungary commercial kit, composed of human 
serum albumin nano-sized colloid particles with a 
diameter of 100–600 nm in the form of sterile 
lyophilized powder. Quality control was performed 
with ascendant paper chromatography.  
Postinjection, we performed dynamic 
acquisition in duration of 30 minutes (30 frames, 60 
seconds per frame, at 256 x 256 x 16 matrix), followed 
by 10 minutes static acquisitions in AP position at 1h, 
2 h, 4 h and 24 h post injection (600 seconds per 
acquisition at 256 x 256 x 16 matrix) using the dual 
headed gamma camera Mediso DHV Nucline Spirit. 
We used cobalt source Featherlite Co57 flood source 
MED 3709 for body contour drawing, and the SLN 
detection was performed with gamma detection probe 
EUROPROBE SYSTEM CE 0459. 
The other 40 pts were treated conventionally 
(surgically) without SLN detection and were 
considered as a control group for 5-year survival rate 
and disease recurrence comparison between the two 
groups. All 80 CRC patients (40 pts with SLN 
detection and 40 pts without SLN detection) 
underwent the same standard surgical technique (total 
mesocolic or mesorectal excision) which included 
resection with systemic lymphadenectomy. Promptly 
after resection, ex vivo, the gamma probe was used to 
detect the SLN or SLNs, and anatomic diagram was 
included to detect possible aberrant lymph node 
drainage. 
Pathohistology (HE and 
immunohistochemistry) was performed to all of the 
resected lymph nodes, including the SLN. First HE 
staining was performed (multi-slice), and if the LN was 
negative, immunohistochemistry was performed with 3 
Ab (CK20, CEA and EMA) using the technique Avidin 
Biotin Immunoperoxidase complex and EnVision 
(Dako, Denmark) visualization system. To avoid false 
positive results (reticulum cells or plasma cells), 
positive cytokeratin cells were considered as tumour 
cells only when they presented cytomorphological 
characteristics of a malignant cell. All tumour cell 
deposits of 2 mm and larger were considered as 
metastasis, deposits of 0.2 - 2 mm were considered 
as micrometastases (MM), and clusters below 0.2 mm 
were considered as isolated tumour cells (ITC). 
 
 
 
Results  
 
Before the trial initiation, a pilot study 
(learning curve) was performed on ten patients 
following the exact design as the main study [13]. It 
included six men and four women, mean age 63 ± 
nine years, classified preoperatively as stage I or II 
CRC. The learning curve presented the following 
results: identification rate of 100%, the accuracy of 
90% and sensitivity of 87.5%. 
 
Figure 1: Scintigraphic images obtained during the learning curve-
dynamic scintigraphy phase. Bold arrows pointing at the site of 
early SLN presentation 
 
The first preliminary results from our pilot 
study were in favour of the main trial initiation and 
correlated with the scientific data worldwide (14-16). 
 
Figure 2: Scintigraphic images obtained during the learning curve-
static acquisition 24h post injection. The circle presents the late 
SLN presentation 
 
We have performed the SLN mapping using 
radiocolloid in 45 pts so far, but 5 of them were 
excluded intra- or postoperatively due to exclusion 
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criteria (1 due to microscopic carcinosis and four due 
to substantial infiltration or Tu perforation), so the final 
number of pts that met the inclusion criteria was 40. 
The preoperative staging of the patients and 
the size of a primary tumour were in correlation with 
the inclusion criteria. 
Table 3: Gender distribution and tumour localization 
Number of patients: 40  
Gender  Male  (27 pts) 67.5 %  
 
Female  (13 pts) 32.5 %  
Tu localization  Left colon  (20 pts) 50%  
 
Transversal colon  (10 pts) 25%  
 
Right colon  (7 pts) 17.5%  
 
Rectum  (3 pts) 7.5%  
 
The average number of lymph nodes 
analyzed pathohistologically after resection was 14±2 
(all pts had at least 12 or more LN analyzed, 
according to the gold standard set by AJCC/UICC 
recommendations). 
Table 4: Preoperative (relative) staging of pts and the size of a 
primary tumour 
Number of patients: 40 
Stage  Stage I   (13 pts) 32.5%  
 Stage 
IIA  
 (11 pts) 27.5%  
 Stage 
IIB  
 (12 pts) 30%  
 Stage 
IIC  
 (4 pts) 10%  
T (size) – Primary tumor  T1  9pt  
 T2  6pt  
 T3a/b 22pt  
 T4a  3pt  
 
The identification of SLNs using the 
radiocolloid method in our study was 38/2, which 
means that out of 40 performed procedures the SLN 
has not been detected only in two of them thus the 
detection rate in our study was 95%. In 2 pts two 
SLNs have been detected. The distance of the 
detected SLNs vs the tumour location was 
respectively: 1-3 cm in 15 pts, 3-5 cm in 13 pts and 5-
10 cm in 10 pts. 
Table 5: Distribution of pts with detected SLNs 
Positive regional LN  Negative regional LN  
True positive - a  15  True negative - d  20  
False negative - c  3  False positive - b  /  
    
Sum  18   20  
 
Out of the 38 pts with detected SLNs, after 
the histopathological analysis, the distribution of true 
positive (SLN is positive, and other regional LNs are 
positive), true negative (SLN is negative, and other 
regional LNs are negative), false negative (SLN is 
negative, but some of the regional LNs are positive) 
and false positive (/) pts was as shown in Table 3. 
Considering the data presented in Table 3, we 
have calculated the following parameters. 
In 5 patients (12.5%), the SLN was the only 
positive lymph node for metastases of all examined 
LNs (relative upstaging). The detection of 
metastases/micrometastases (N+) with 
immunohistochemistry, after negative HE staining 
(No), using the 3 Abs, was positive in 2 pts, so the 
upstaging in our study was 10% (true upstaging). 
Table 6: Sensitivity, Accuracy, Negative predictive value and 
Detection rate parameters 
Parameter Formula Value 
Sensitivity [a / (a+c)] x 100 83.3% 
Accuracy [(a+d) / (a+b+c+d)] x 100 92.1% 
Negative predictive value [d / (d+c)] x 100 86.95 % 
Detection rate 38/40 pt x 100     95.0% 
Parameter Formula Value 
Sensitivity [a / (a+c)] x 100 83.3% 
Accuracy [(a+d) / (a+b+c+d)] x 100 92.1% 
Negative predictive value [d / (d+c)] x 100 86.95 % 
Detection rate 38/40 pt x 100     95.0% 
 
SLNs with higher colloid uptake (1821 ± 972 
counts per 10 seconds) were free of metastases (p < 
0.05) compared to SLNs with lower colloid uptake 
(884 ± 431 counts per 10 seconds) that were positive 
for metastatic deposits (p < 0.01). Our data analysis 
presented a strong correlation between the size of a 
tumour and the metastatic involvement of SLNs. The 
number of pts with positive SLNs increased with the 
increase of the primary tumour size (p < 0.001). 
Table 7: Correlation between size of a tumour and metastatic 
involvement of SLN 
Correlation between size of tumor and metastatic involvement of SLN 
Size of tumor and type of SLN Number of patients Percentage 
Positive SLN; Tu ≤ 1cm. 2 5.2% 
Positive SLN; Tu 1-2 cm. 6 15.8% 
Positive SLN; Tu > 2 cm. 10 26.3% 
Negative SLN; Tu ≤ 1 cm. 16 42.1% 
Negative SLN; Tu 1-2 cm. 3 7.9% 
Negative SLN; Tu > 2 cm. 1 2.7% 
All 38             100.0% 
 
 
 
Discussion  
 
One of the most important factors for 
prognosis in colorectal cancer patients is the status of 
the regional lymph nodes included in the TNM 
classification. The SLN is the first node that drains a 
tumour and hence it is most likely to become positive 
for metastases. A precise identification and PH 
analysis of the SLN will improve the tumour staging, 
and consequently, a more appropriate postoperative 
treatment can be sought. High-risk stage II patients 
have worse survival rates and five-year disease free 
period compared to stage IIIA patients. Restaging and 
upstaging of high-risk stage II patients into stage III 
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(based on the positive LN status) could improve their 
survival rate by 33% and five-year disease free period 
by 40% due to the inclusion of adjuvant 
chemotherapy. SLNB (sentinel lymph node biopsy) is 
currently accepted as the standard method of the 
evaluation of the axillary status of breast cancer pts 
and the management of malignant melanoma pts. 
Almost 75% of early staged (stage I and II) breast 
cancer pts benefit from the technique regarding 
modification of the extent of the axillary dissection 
[11]. The SLN detection concept in CRC pts inflicts no 
reduction or alteration in the surgical procedure, but 
staging accuracy improvement especially in the 
subgroup of high-risk stage II pts [17]. The possibility 
for ultra-staging could either confirm the LN free 
disease in stage II pts or classify them as real stage II, 
thus helping them to avoid the unnecessary adjuvant 
therapy or upstage the LN positive stage II pts into 
stage III, thus improving their overall survival rate due 
to adjuvant chemotherapy inclusion. 
The first publications on SLN detection in 
CRC pts used blue dye and presented poor results 
with low sensitivity and detection rate of only 70%. 
However, with improved study design, increased 
number of pts and especially with SLN detection 
method standardization, the detection rate increased 
up to 97%, accuracy up to 90,7% and upstaging rate 
up to 27% [18]. The meta analysis performed in 2012 
by E. S. van der Zaag et al. on 57 relevant 
publications using blue dye for SLN detection in 3934 
CRC pts presented the following results: detection 
rate of 90.7%, the sensitivity of 69.6% and upstaging 
of 18.9% [19]. Up to date, all scientific data 
concerning this issue suggests that even though the 
detection rate and the upstaging rate improved, the 
sensitivity of the SLN detection method with blue dye 
remains low. Due to the small particle size, blue dye 
travels through the lymphatic channels relatively 
quickly and rapidly passes on to the second echelon 
LNs [20, 21]. In that manner, at least 4 LNs are 
considered to be SLNs when using the blue dye 
detection method and at least four coloured LNs must 
be analyzed. 
Radiocolloid particles are bigger and travel 
through the lymphatic channels at a much slower rate. 
Larger colloids yield a significantly higher count rate 
probably due to slower clearance from the LNs. 
Furthermore, radiocolloids are incorporated in the first 
echelon LNs by phagocytosis and remain trapped for 
a longer period when compared to blue dye, making 
the LNs detected with this method more likely to be 
true SLNs [21, 22]. Among the first SLN detection 
studies in CRC pts using radiocolloid particles 
(antimony sulphide labelled with 99 mTc), applying the 
ex vivo injection technique, was the study conducted 
by Merrie AE et al. in 2001 and it presented detection 
rate of 88% and sensitivity of 55% [23]. Kitagava et al. 
reported the first study of SLN mapping in 56 CRC pts 
using the preoperative endoscopic injection of 
technetium labelled colloids with a detection rate of 
91% and accuracy of 92% [24]. The 2012 study by De 
Haas R.J. et al. also used the preoperative 
endoscopic application of radiocolloid as a single 
tracer for SLN detection in CRC pts and presented 
detection rate of 86% and upstaging rate of 17% [25]. 
In our study, we used the preoperative 
endoscopic method of application of radiocolloid, 24 h 
before the operation, with three peritumoral and one 
intratumoral injection thus covering the whole 
lymphatic tumour drainage based on our previous 
experience [11]. The statistical analysis presented the 
following data: sensitivity 83.3%, accuracy 92.1%, and 
negative predictive value 86.95% and detection rate of 
95%. We failed to detect the SLN in 2 pts, and both of 
them were pts with rectal carcinoma. Most of the 
publications exclude the rectal carcinoma due to its 
different pattern of spread. We decided to include the 
pts with rectal carcinoma in our study and 2 out of 3 
pts included the detection of SLN with our method 
failed. This finding is in correlation with the scientific 
data in other published studies. The number of pts 
with rectal carcinoma included in our study is not 
sufficient for a firm conclusion concerning the issue of 
whether the SLN detection method using radiocolloids 
should be incorporated into the management 
guidelines of this subgroup of pts. Other possible 
reasons for unsuccessful SLN mapping that are 
mentioned in the literature could be intraluminal 
injection, incomplete circumferential injection or large 
primary tumour size [21]. Both of our pts had T3 
primary tumour size which also could have contributed 
to the omission of SLN detection. Since all the 
endoscopic procedures were performed by the same 
endoscopist with large experience in the field of 
endoscopy and were also video monitored, we 
exclude the possibility of not detecting the SLN to be 
due to inappropriate injection of the radiocolloid. 
All three false negative pts had advanced 
tumour size: two of them were T3b primary tumour 
size, and one was T4a, which might have contributed 
to the false negative results of the SLN analysis due 
to possible skip metastases. Large primary tumour 
size disrupts the lymphatic drainage and alters the 
lymphatic flow patterns [21]. No aberrant drainage 
was noted in our study. 
The average number of lymph nodes 
analyzed pathohistologically after resection was 14 ± 
two which is a reflection of a sufficient oncological 
resection. All pts had at least 12 or more LNs 
analyzed, according to the gold standard for the 
obligatory minimal number of analyzed LNs, set by 
AJCC/UICC recommendations. In 5 patients (12.5%), 
the SLN was the only positive lymph node for 
metastases of all examined LNs (relative 
upstaging).The detection of 
metastases/micrometastases (N+) with 
immunohistochemistry, after negative HE staining 
(No), using the 3 Abs, was positive in 2 pts, so the 
upstaging in our study was 10% (true upstaging). The 
2012 meta analysis by Nuh N.Rahbari on 4087 pts 
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from 39 relevant studies concluded that the detection 
of MM and ITC is associated with worse overall 
survival rate and increased loco regional disease 
recurrence of 23% vs 7% of the disease free LNs [26]. 
This scientific data suggests that not only metastases 
of 2 mm in size or bigger, but also MM and ITC should 
be considered for CRC pts upstaging [26]. 
SLNs with higher colloid uptake were free of 
metastases vs SLNs with lower colloid uptake, most 
probably due to lymph node destruction from the 
metastatic tissue. Our data analysis presented a 
strong correlation between the size of a tumour and 
the metastatic involvement of SLNs. The number of 
pts with positive SLNs increased with the increase of 
the primary tumour size.  
In conclusion, our results confirm that the SLN 
detection technique implemented in this study is not 
invasive, safe, with reliable detection rate, accuracy, 
sensitivity, negative predictive value, upstaging rate 
and should be incorporated into the surgical 
guidelines in our country concerning the subset of 
high-risk stage II CRC pts. SLNs with higher colloid 
uptake more often were free of metastases, while the 
occurrence of metastatic SLNs correlated positively 
with primary tumour size. We plan to continue this 
study up to a minimum of 100 pts, using the 
SPECT/CT modality, and we expect that this would 
further improve the reliability of our method and 
contribute to the diagnosis and upstage of the CRC 
patients, which is important for the postoperative 
oncology treatment protocols. 
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